Alnylam Pharmaceuticals Inc annual net income for fiscal TTM was $577 million, an increase of 83.8% from $314 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $577M | $314M | ($278M) | ($440M) | ($1.1B) | ($853M) | ($858M) | ($886M) | ($761M) | ($491M) | ($410M) | ($290M) | ($360M) | ($89M) | ($106M) | ($58M) | ($44M) | ($48M) | ($26M) | ($85M) | ($35M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $206M | $186M | $251M | ($66M) | ($57M) | ($84M) | ($112M) | ($17M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ALNY metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ALNY financial statements → Interactive ALNY charts →
About TickerBase · Data methodology & sources